Aller au contenu principal
Profil bibliographique

R Nhema

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

7Publications signalées
217Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

HIV-related health complications and treatmentsHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and TreatmentBiological Research and Disease Studies

Les publications récentes

Accès ouvert 2024 article OpenAlex

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa

Victor Riitho, Roisin Connon, Agnes Gwela, Josephine Namusanje et autres

One-third of people with HIV in sub-Saharan Africa start antiretroviral therapy (ART) with advanced disease. We investigated associations between immune biomarkers and mortality in participants with advanced HIV randomised to cotrimoxazole or enhanced antimicrobial prophylaxis in the Reduction of Early Mortality in …

Kenya, gb, Ouganda, Zimbabwe (code pays fourni par la source)

15 citations Nature Communications
Accès ouvert 2020 article OpenAlex

Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status

Sarah Pett, Moira Spyer, Lewis Haddow, R Nhema et autres

OBJECTIVES: To assess baseline prevalence of cryptococcal antigen (CrAg) positivity; and its contribution to reductions in all-cause mortality, deaths from cryptococcus and unknown causes, and new cryptococcal disease in the REALITY trial. DESIGN: Retrospective CrAg testing of baseline and week-4 plasma samples …

au, gb, Zimbabwe, Ouganda, Malawi, Kenya (code pays fourni par la source)

1 citation AIDS
Accès ouvert 2018 article OpenAlex

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

JA Thompson, Cissy Kityo, David Dunn, Anne Hoppé et autres

BACKGROUND: Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs in low-income countries often delays detection of treatment failure. The impact of remaining on failing protease inhibitor (PI)-containing regimens is unclear. METHODS: We retrospectively tested VL in 2164 stored …

gb, Ouganda, ca, Zimbabwe, Malawi, es, sg (code pays fourni par la source)

12 citations Clinical Infectious Diseases
Accès ouvert 2018 article OpenAlex

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

Jane Mallewa, Alexander J. Szubert, Peter Mugyenyi, Ennie Chidziva et autres

BACKGROUND: In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-to-use supplementary food (RUSF) would increase early weight gain, thereby reducing early mortality …

gb, Malawi, Ouganda, Zimbabwe, Kenya, au (code pays fourni par la source)

32 citations The Lancet HIV
Accès ouvert 2018 article OpenAlex

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

Abraham Siika, Leanne McCabe, Mutsa Bwakura‐Dangarembizi, Cissy Kityo et autres

Background: Severely immunocompromised human immunodeficiency virus (HIV)-infected individuals have high mortality shortly after starting antiretroviral therapy (ART). We investigated predictors of early mortality and "late presenter" phenotypes. Methods: The Reduction of EArly MortaLITY (REALITY) trial enrolled ART-naive adults and children ≥5 years …

Kenya, gb, Zimbabwe, Ouganda, Malawi (code pays fourni par la source)

35 citations Clinical Infectious Diseases
Accès ouvert 2017 article OpenAlex

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, JA Thompson, Cissy Kityo, Anne Hoppé et autres

BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the …

Zimbabwe, gb, Ouganda, Malawi, Kenya, Zambie, sg (code pays fourni par la source)

42 citations The Lancet Infectious Diseases
Accès ouvert 2017 article OpenAlex

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Leonard Bagenda, Joep J. van Oosterhout, Silvia Bertagnolio et autres

BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the …

sg, gb, Ouganda, Zimbabwe, Malawi, ch (code pays fourni par la source)

80 citations The Lancet HIV

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.